<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019248</url>
  </required_header>
  <id_info>
    <org_study_id>2021-1474</org_study_id>
    <nct_id>NCT05019248</nct_id>
  </id_info>
  <brief_title>Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine</brief_title>
  <acronym>CIRMS</acronym>
  <official_title>A Non-interventional Observation Study to Evaluate Immune Responses Following Seasonal Influenza Vaccine in Participants With Relapsing Multiple Sclerosis Treated With Cladribine Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to characterize the antibody response to seasonal&#xD;
      influenza vaccine, in patients with active RRMS, treated with cladribine, compared to control&#xD;
      individuals with basic immunomodulatory treatment. Serum antibody titers against the&#xD;
      respective pathogen will be assessed prior to and 6 to 8 months following vaccination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion who achieve seroprotection</measure>
    <time_frame>6 months</time_frame>
    <description>The capacity of influenza vaccine to elicit a measurable immune response (immunogenicity) when it is administered (i) shortly (at least 4-6 weeks) before cladribine initiation (cohort 1), (ii) 3 to 4 months after cladribine initiation (cohort 2) (iii) shortly (at least 4-6 weeks) before second cladribine administration (cohort 3) and (iv) in patients who have already received the second cycle of cladribine tablets (3 to 4 months after second cycle; cohort 4), compared to RRMS patients treated with basic DMTs (cohort 5). Efficacy is measured as proportion of patients who achieve seroprotection (specific hemagglutination inhibition (HI) titers &gt; 1:40)).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fraction with 2-fold increase of HI titers</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who achieve a 2-fold increase in specific HI titers at 6 to 8 months post-immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction with 4-fold increase of HI titers</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who achieve a 4-fold increase in specific HI titers at 6 months post-immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with seroconversion (i.e., a pre-vaccination antibody titer &lt; 10 and a post-vaccination HI titer &gt; 40)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean antibody titers</measure>
    <time_frame>6 months</time_frame>
    <description>Geometric mean antibody titers (GMTs) and geometric mean antibody ratios (GMRs, post-vaccination:pre-vaccination) prior and 6 months after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular immune responses</measure>
    <time_frame>6 months</time_frame>
    <description>Flow cytometry analysis, which will include (but is not limited to) the following cells: Total B cells (CD19 positive), B-cell subsets, e.g., memory B cells, na√Øve B cells, plasma cells; Total T cell (CD3 positive) and T cell subsets, e.g. T helper cells, cytotoxic lymphocyte T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum immunoglobulin subtypes</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis of quantitative Ig levels (including total Ig, IgG, IgG subtypes, IgM, and IgA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza infections</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of infections caused by influenza</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <condition>Vaccine Response Impaired</condition>
  <arm_group>
    <arm_group_label>vaccination prior to first cladribine exposition</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccination shortly after first cladribine exposition</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccination prior to second cladribine exposition</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccination following completion of cladribine treatment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccination in patients with RRMS not subjected to cladribine</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Most recent vaccine to seasonal influenza</intervention_name>
    <description>Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).</description>
    <arm_group_label>vaccination following completion of cladribine treatment</arm_group_label>
    <arm_group_label>vaccination in patients with RRMS not subjected to cladribine</arm_group_label>
    <arm_group_label>vaccination prior to first cladribine exposition</arm_group_label>
    <arm_group_label>vaccination prior to second cladribine exposition</arm_group_label>
    <arm_group_label>vaccination shortly after first cladribine exposition</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      (I) Serum samples for assessment of antibody levels (II) Peripheral blood mononuclear cells&#xD;
      for assessment of cellular immune responses&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        52 patients per group/cohort, resulting in a theoretical maximum number of 260 patients.&#xD;
        Patients will be screened until this number is reached.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form (ICF)&#xD;
&#xD;
          2. Age 18 to 60 years old (inclusive) as of the date the ICF is signed&#xD;
&#xD;
          3. Diagnosis of RRMS according to the revised McDonald criteria&#xD;
&#xD;
          4. EDSS score of 0.0 to 7.0 (inclusive)&#xD;
&#xD;
          5. In case of participants who are subjected to influenza vaccination by the treating&#xD;
             physicians prior to cladribine the first or second cycle of cladribine (cohort 1 +&#xD;
             cohort 3), this should be performed at least 4 to 6 weeks before the start of&#xD;
             cladribine.&#xD;
&#xD;
        Definition of control group:&#xD;
&#xD;
        Patients with active RRMS treated with cladribine will be compared to sex and age matched&#xD;
        control individuals, with RRMS under basic treatment either with interferon beta,&#xD;
        glatiramer acetate, dimethyl fumarate or teriflunomide, who provide sample material prior&#xD;
        to and 6 to 8 months after routine seasonal influenza vaccination during the same period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with B-cell targeted therapies (e.g., rituximab, ocrelizumab,&#xD;
             atacicept, belimumab, or ofatumumab)&#xD;
&#xD;
          2. Any previous treatment with alemtuzumab, cladribine, cyclophosphamide, mitoxantrone,&#xD;
             azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body&#xD;
             irradiation, or bone marrow transplantation&#xD;
&#xD;
          3. Medical, psychiatric, cognitive, or other conditions that, in the investigator's&#xD;
             opinion, compromise the patient's ability to understand the patient information, to&#xD;
             give informed consent, or to complete the study&#xD;
&#xD;
          4. Patients that receive immunosuppressive treatment for diseases other than MS or that&#xD;
             receive long-term corticosteroid treatment&#xD;
&#xD;
          5. Patients that received apheresis procedures 6 weeks prior to vaccination or in-between&#xD;
             vaccination and DMT initiation&#xD;
&#xD;
          6. Systemic high dose corticosteroid therapy within 6 weeks prior to vaccination or&#xD;
             in-between vaccination and DMT initiation&#xD;
&#xD;
          7. Patients with verified infection by human-immunodeficiency-virus or hepatitis-c-virus&#xD;
&#xD;
          8. Patients with major impairment of the blood coagulation system including therapy with&#xD;
             anticoagulants&#xD;
&#xD;
          9. Patients with known chicken egg allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven G Meuth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich-Heine-University Duesseldorf, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven G Meuth, MD, PhD</last_name>
    <phone>0049 211 81 19532</phone>
    <email>svenguenther.meuth@med.uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leoni Rolfes, MD</last_name>
    <phone>0049 211 81 19532</phone>
    <email>leoni.rolfes@med.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Faculty, Heinrich-Heine-University</name>
      <address>
        <city>Duesseldorf</city>
        <state>Northrhine-Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leoni Rolfes, MD</last_name>
      <phone>0049 211 81 19532</phone>
      <email>leoni.rolfes@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza vaccination</keyword>
  <keyword>cladribine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

